dpp4 and glp-1 Design principles of long-acting DPP-4 inhibitors dpp-4_inhibitors [TUSOM | Pharmwiki]

The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument

It is a pressure and coordination issue

For some users, switching to an oral GLP-1 formulation eliminates injection site reactions entirely

To minimise gastrointestinal discomfort when taking both medications, consider the following practical strategies: take your antibiotic with food (unless specifically instructed otherwise), stay well-hydrated by drinking plenty of water throughout the day, and eat smaller, more frequent meals rather than large portions

Starting with a smaller serving and gradually increasing helps the body adjust comfortably

1 Even though this slowdown in gut motility is by design, it also may be the reason many people on GLP-1 medications experience some initial digestive disturbances and discomfort